|
Last Updated: Nov 18, 2006 - 12:32:53 PM |
Latest Research
:
Pharmacology
:
Antivirals
:
Bavituximab
Phase Ib Trial Is Evaluating Bavituximab Administered With Common Chemotherapy Regimens
Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted therapeutics for the treatment of cancer and hepatitis C virus (HCV) infection, today announced initiation of patient treatment in its Phase lb clinical trial to evaluate its lead anti-phospholipid immunotherapy agent bavituximab given in combination with common cancer chemotherapy agents. The trial is expected to enroll up to 12 patients at three clinical sites in India.
Nov 17, 2006 - 10:32:00 PM
Latest Research
:
Pharmacology
:
Antivirals
:
Bavituximab
Complete Inhibition of Viral Replication in H5N1 In Vivo Model by Bavituximab
Peregrine Pharmaceuticals, a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for the treatment of hepatitis C virus (HCV) infection and cancer, today announced that its lead anti-viral compound bavituximab (formerly Tarvacin) completely inhibited replication of a laboratory strain of the H5N1 virus, commonly known as avian flu, in fertilized chicken eggs, an in vivo model for influenza anti- viral activity. These preliminary findings will be reported today at the 106th general meeting of The American Society for Microbiology (ASM) in Orlando, Florida by Dr. Philip Thorpe, a member of the Peregrine Scientific Resource Board and professor of pharmacology at the University of Texas Southwestern Medical Center at Dallas. Bavituximab, a monoclonal antibody with unique anti-viral and anti-cancer properties, has already demonstrated good tolerability in a Phase l trial in patients with HCV infection.
May 25, 2006 - 1:09:00 PM
<< prev
next >>
|
